Adjuvant Therapy for Resected Biliary Tract Cancer

Publication Date: March 11, 2019
Last Updated: December 15, 2022

Treatment

Patients with resected biliary tract cancer should be offered adjuvant capecitabine chemotherapy for a duration of 6 months. ( EB , H , H , M )
Qualifying statements:
  • In the BILCAP phase III randomized controlled trial, capecitabine was delivered at a dose of 1250 mg/m2 twice/day on treatment day 1 to 14 of a 3-weekly cycle for 24 weeks (8 cycles).
  • The Expert Panel agrees that the recommended dose of capecitabine may be determined by institutional and regional practices.
3336

Overview

Title

Adjuvant Therapy for Resected Biliary Tract Cancer

Authoring Organization